These data would indicate that the effect of FTY720 potentiating sensitivity of breast cancer cell to doxorubicin is probably via CIP2A downregulation and suggest a potential enhanced antitumor efficacy of a combination between FTY720 and bortezomib that should be explored. Here, CIP2A is linked to breast carcinoma.